NCT01827137View on ClinicalTrials.gov

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

December 7, 2016

Study Completion Date

November 6, 2017

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

Galinpepimut-S

Galinpepimut-S admixed with the adjuvant Montanide following specified schedule

BIOLOGICAL

GM-CSF

subcutaneous injection

OTHER

Montanide

adjuvant

DRUG

lenalidomide

optional post-ASCT therapy

DRUG

bortezomib

optional post-ASCT therapy

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

Sellas Life Sciences Group

INDUSTRY